

Position Statement

Treatment	Botulinum Toxin Type A
<p>Commissioning position</p>	<p>The use of botulinum toxin type A is supported in the following indications for people registered with a Worcestershire GP or resident within Worcestershire and not currently registered with any GP:</p> <ul style="list-style-type: none"> • Anal fissures, after three months with standard treatment for chronic anal fissures. • Blepharospasm and hemifacial spasm. • Probable contracture of joint in multiple sclerosis, in conjunction with prolonged stretching modalities (NICE Clinical Guideline 8). • Focal dystonia, where other measures are inappropriate or ineffective. • Focal spasticity in patients with upper motor neurone syndrome, caused by cerebral palsy, stroke, acquired brain injury, multiple sclerosis, spinal cord injuries and neurodegenerative disease, where other measures are inappropriate or ineffective. • Idiopathic cervical dystonia (spasmodic torticollis). • Prophylaxis of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) that has not responded to at least three prior pharmacological prophylaxis therapies, and whose condition is appropriately managed for medication overuse (i.e. in line with NICE TA 260). • Refractory detrusor overactivity, in line with local care pathway and NICE Clinical Guideline 171, where conservative therapy (including overactive bladder drug therapy) has failed. • Sialorrhea (excessive salivary drooling), when all other treatments have failed. <p>Where the use of botulinum toxin type A is used to treat an indication outside of the manufacturer's marketing authorisation, clinicians and patients should be aware of the particular governance requirements, including consent, for using drugs off-label.</p> <p>Botulinum toxin type A is not routinely commissioned in the following indications:</p> <ul style="list-style-type: none"> • Canthal lines (crow's feet) and glabellar (frown) lines • Hyperhidrosis • Any other indication not listed as supported above <p>For patients with conditions which are not routinely commissioned, as indicated above, requests will continue to be considered by Worcestershire Clinical Commissioning Groups through the individual funding request process, if there is evidence that the patient is considered to have clinically exceptional circumstances to any other patient experiencing the same condition within Worcestershire. Requests to commission the use of botulinum toxin as an option to treat other indications, where a known cohort of patients can be identified, should be processed by application to the Worcestershire Area Prescribing Committee (APC).</p>
<p>Date</p>	<p>3rd June 2014</p>
<p>Date for review</p>	<p>June 2017, or sooner if a new drugs application for an unapproved indication is submitted to the Worcestershire APC or national guidance is made available.</p>